Budget impact of molgramostim
1 evidence topic · 1 source
Summary
No product-specific budget impact model is included in this report. The Dutch horizon scan gives an expected annual cost per patient of €100,000–500,000. This is a horizon-scan estimate, not an observed U.S. average sales price or an announced U.S. wholesale acquisition cost.